The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% during the forecast period. Increased prevalence of infectious and bacterial diseases, increased investment to accelerate the development of novel antibiotic therapies for infectious diseases, and an increasing number of R&D projects to discover and develop new antibiotics are factors expected to drive market revenue growth. Furthermore, antibiotics are often employed to avoid contamination in the manufacturing of bacterial and viral vaccines, which is expected to boost market revenue growth.
Growing demand for therapeutic antibodies, particularly monoclonal and polyclonal antibodies, is expected to drive market growth over the forecast period. Antibodies are the most used biopharmaceuticals for selectively targeting abnormal cells. As a result, several pharmaceutical companies have begun to concentrate on the development of improved treatment of acute and chronic ailments such as cancer and rheumatoid arthritis. Another major factor driving growth of the antibody production market is the approaching expiration of patent of numerous effective monoclonal antibodies. In a few years, several antibodies, including Humira, Keytruda, and Herceptin will lose their patents. Biosimilars are being developed by many companies for trastuzumab, including Pfizer Inc. and Amgen Inc., and, which is expected to drive market growth.
Driver: Increased demand for therapeutic antibodies is driving antibody production market growth
Monoclonal antibodies (mAbs) are medications used to treat cancer, autoimmune disorders, and inflammatory illnesses. The global need for monoclonal antibodies is increasing due to the incidence of infectious diseases. Healthcare reforms in emerging economies, as well as increased investment in the antibodies production market, is expected to drive the market revenue growth during the forecast period.
Therapeutic antibodies are becoming increasingly important since they have been the primary therapy technique for a variety of disorders during the last 25 years. During this period, significant technical improvements have accelerated and improved mAbs treatment. According to the U.S. Food and Drug Administration (FDA), 48 novel mAbs have been authorized since 2008, adding to a total global market of 100 monoclonal antibodies in clinical use by the end of 2021. Monoclonal antibodies have developed as a prominent class of therapeutic agents in the treatment of many diseases, particularly malignancies, neurological, and metabolic disorders, because of the highly active development of antibody medicines in recent decades. Until the late 1990s, when the first chimeric mAbs were authorized, revenue growth and regulatory approval of mAbs medicines were slow. Following the approval of humanized and subsequently completely human mAbs, the rate of product approvals and revenue of mAb products has grown significantly. The massive growth of mAb products is expected to be a primary driver for market revenue growth.
Monoclonal antibodies offer an alternate method of COVID-19 prevention. Monoclonal antibody passive infusion pre-or post-exposure treatment may provide rapid protection against infection that may persist for weeks or months. In some cases, newer methods that change monoclonal antibodies' Fc region to make antibodies last longer can offer levels that could be protective for months.
Restraint: Lack of skilled professionals is a key factor restraining revenue growth
Therapeutic monoclonal antibodies (mAbs) are the fastest-growing class of new therapeutic compounds that are not already on the market. However, current manufacturing and purifying methods limit the number of therapeutic antibodies that can be made, which increases the cost. In-vivo genetic delivery of therapeutic monoclonal antibodies could be a new way to solve these problems. In the first place, therapeutic effectiveness can be increased by keeping therapeutic, non-toxic levels of drugs in the blood for a very long time. Repeated high-dose bolus injections may not be necessary, which could reduce the risk of side effects. There is a chance that the cost of making and purifying therapeutic antibodies could be cut, making mAb gene transfer both in and out of the body an economically viable and appealing option.
The antibody market has been growing owing to rising demand for monoclonal antibodies (mABs) as a result of the COVID-19 pandemic. The FDA granted an Emergency Use Authorization (EUA) for three monoclonal antibodies designed for outpatient treatment of symptomatic COVID-19 patients in response to the high transmission and severe fatality rates. The Centers for Medicare and Medicaid Services approved monoclonal antibody therapies such as "REGN-COV2,(which is a combination treatment consisting of 2 human monoclonal antibodies, Casirivimab & imdevimab) and bamlanivimab in November 2020 and April 2021, respectively.. This helps to block the virus from invading human cells. COVID-19 patients can be administered a monoclonal antibody intravenously (IV) at an emergency department or an Infusion Center. According to a report by the National Center for Biotechnology Information, the U.S. government purchased 2.5 million monoclonal antibody therapies and distributed 1 million to states.
Process Type Outlook:
Based on process type, global antibody production market has been segmented into upstream processing, downstream processing, and filtration.
Upstream processing segment is further segmented into bioreactors and consumables. The upstream segment accounted for a significantly large revenue share in 2021. Increased application of process analytical technology strategy as a mechanism to design, evaluate, and improve processes through rapid measurements of essential process parameters is one of the key reasons driving the segment growth. Process Analytical Technologies (PAT) has been used to investigate the performance of cell culture production based on characteristics such as real-time nutritional analysis and inline cell density monitoring. This, in turn, affects the Critical Quality Attributes (CQA) of the total upstream bioprocessing and helps to improve process productivity. Furthermore, increasing cell line productivity has significantly improved upstream processing performance and process reproducibility, as highly productive cultures require low operating costs and the use of smaller bioreactors. The paradigm change from traditional stainless-steel bioreactors to single-use products has resulted in significant production benefits for upstream applications. Abzena, a biopharmaceutical firm, chose Sartorius Stedim Biotech to build its Bristol-based facilities in a single-use (SU) format in response to growing acceptance of single-use technology. Furthermore, the use of a high throughput bioreactor system allows to determine optimal media formulation and optimize process parameters, and operating conditions in order to identify the high titer-producing cell line. This encourages the use of upstream bioprocessing processes.
Antibody Type Outlook:
Based on antibody type, global antibody production market has been segmented into monoclonal antibodies, polyclonal antibodies, and others.
Monoclonal antibodies segment revenue is expected to register a significantly robust revenue growth over the forecast period. Monoclonal antibodies play a vital role in the prevention or treatment of many viral illnesses. Several monoclonal antibodies are being tested in human clinical trials to see if they can reduce or change SARS-CoV-2 infection. Furthermore, a drug that consistently inhibited COVID-19 development would significantly lessen the fears and unreliability linked with SARS-CoV-2 infection and would give clinicians a treatment tool that they must-have for all patients. Monoclonal antibodies have the potential to be utilized to cure or prevent the COVID-19 pandemic. This would represent a significant step forward in the treatment of the epidemic.
Antibody production market in North America is expected to account for largest revenue share in the global market during the forecast period owing to several factors including an increase in the geriatric population, increased healthcare expenditure, and continuous growth in R&D activities, as well as an increase in the implementation of these therapeutic applications in the treatment of different disorders such as PCOS (polycystic ovary syndrome) and breast cancer in the U.S. For example, according to a 2019 Centers for Disease Control and Prevention (CDC) report, PCOS affects approximately 6% to 12% of women, representing over 5 million women of reproductive age, and has been recognized as among the most frequent causes of female infertility in the U.S., driving market growth. Moreover, the existence of advanced health infrastructure and direct compensation policies that are well-established are expected to contribute significantly to market revenue growth over the forecast period.
Antibody production market in Asia Pacific is expected to register a steady revenue CAGR over the forecast period owing to growing government backing, constantly changing illness profiles, rising public-private collaborations, and increased funding activities. These factors are boosting the performance of Asia Pacific biotechnology industries. Furthermore, substantial investments support the adoption of innovative technologies in the region's healthcare industry. According to the Organization for Economic Co-operation and Development (OECD), China led the world in R&D expenditure in 2019. Furthermore, governments in Asia Pacific countries provide tax breaks, cheaper lands, incubators, and direct investment assistance to encourage growth of indigenous biotechnology companies, allowing them to enhance their capabilities and capacities. Malaysia, Taiwan, Singapore, India, China, and Japan are among the most appealing locations for the global biotechnology industry.
European antibody production market is expected to account for a significantly large revenue share in the global market during the forecast period. This is owing to the sector's rapid expansion and ongoing innovation and developments. ImmunoPrecise, for example, has launched DeepDisplay, an antibody discovery platform. It has various benefits, including faster human antibody discovery, highly selective panels of antibodies that are therapeutically relevant, and overcoming challenges with complicated cell membrane targets. Furthermore, particularly cost-conscious markets are already shifting to therapeutic antibodies, which are likely to boost the European market's growth rate. Patients also benefit from the growing network of clinics in established and emerging economies, as it promotes accessibility and convenience.
Competitive landscape of global antibody production market is moderately fragmented with many key companies operating at global and regional levels. Key companies are engaged in platform development and strategic alliances to expand their respective portfolios and gain a robust footing in the global market. Major companies in the global market report include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, AstraZeneca, AbbVie Inc., Pfizer Inc., Amgen Inc., and GlaxoSmithKline plc.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides an analysis of market trends in each of sub-segments from 2019 to 2030. For the purpose of this report, Reports and Data has segmented global antibody production market based on process type, antibody type, end-use, and region:
Antibody Production Market Report Scope
Segments covered By Process Type Outlook, Antibody Type Outlook, End-use Outlook, Regional Outlook
By Process Type Outlook
Filtration Consumables & Accessories
By Antibody Type Outlook
Monoclonal Antibodies (mAbs)
By End-use Outlook
Pharmaceutical & Biotechnology Companies
Middle East & Africa